Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITGβ4 siRNA is a small interfering RNA (siRNA) designed to silence the expression of integrin subunit beta 4 (ITGβ4), a junctional protein involved in endothelial barrier stability. In research settings, specifically in human pulmonary artery endothelial cells (HPAECs), ITGβ4 siRNA is utilized to investigate the molecular mechanisms of physiologic and pathologic shear stress. Studies indicate that knockdown of ITGβ4 leads to degraded endothelial barrier function and prevents cell alignment in the direction of flow, highlighting its role as a downstream effector of flow-sensitive transcription factors like KLF4. This reagent is primarily used as a laboratory tool to elucidate the pathophysiology of conditions such as high cardiac output pulmonary hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ITGβ4 siRNA.